AMGN · 10-Q · 2026Q2 · Full report

Product Pipeline Progress

AMGEN INC · 2026-08-05 · Importance 38 · Surprise 60

In June 2026, the European Commission granted marketing authorization for IMDYLLTRA as monotherapy for adults with extensive-stage small cell lung cancer. The authorization covers patients requiring systemic therapy after disease progression on or after first-line platinum-based chemotherapy. The approval was based on the DeLLphi-304 global Phase 3 trial, which demonstrated a significant survival benefit versus chemotherapy. IMDELLTRA/IMDYLLTRA was among the brands driving U.S. and rest-of-world volume growth during the six months ended June 30, 2026.